Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP. de Groot FA, et al. Among authors: doorduijn jk. Eur J Cancer. 2024 Dec;213:115068. doi: 10.1016/j.ejca.2024.115068. Epub 2024 Oct 13. Eur J Cancer. 2024. PMID: 39427440 Free article.
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Electronic address: clinicalguidelines@esmo.org. Ferreri AJM, et al. Among authors: doorduijn jk. Ann Oncol. 2024 May 14:S0923-7534(23)05074-3. doi: 10.1016/j.annonc.2023.11.010. Online ahead of print. Ann Oncol. 2024. PMID: 38839484 Free article. No abstract available.
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Ferreri AJM, et al. Among authors: doorduijn jk. Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38836097 Free PMC article.
Primary central nervous system lymphoma.
de Koning ME, Hof JJ, Jansen C, Doorduijn JK, Bromberg JEC, van der Meulen M. de Koning ME, et al. Among authors: doorduijn jk. J Neurol. 2024 May;271(5):2906-2913. doi: 10.1007/s00415-023-12143-w. Epub 2023 Dec 19. J Neurol. 2024. PMID: 38112784 Review.
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: doorduijn jk. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: doorduijn jk. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Le Gouill S, et al. Among authors: doorduijn jk. Haematologica. 2024 Jan 1;109(1):343-350. doi: 10.3324/haematol.2022.282469. Haematologica. 2024. PMID: 37470152 Free PMC article. No abstract available.
90 results